Nomination committee appointed As per specifications set at Meda's 2008 annual general meeting, a nomination committee has been appointed. It consists of: Karl-Magnus Sjölin, Committee Chairman, Stena Sessan Rederi AB Eva Halvarsson, the Second AP Fund Peter Rudman, Nordea's funds Kerstin Stenberg, Swedbank Robur funds Peter Sjöstrand, Meda's board chairman Karl-Magnus Sjölin, Committee Chairman ph. +46 31-774 35 35 Anders Larnholt, Vice President Investor Relations ph: +46 709-458 878 MEDA AB (publ) is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented by its own organisations in about 40 countries. Meda's products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit www.meda.se.
Nomination committee appointed
| Source: Meda AB
Attachments
